Full text is available at the source.
Using Aptamer-Guided mRNA to Improve Immunotherapy
Updated
Abstract
A fourfold increase in CD4+ T-cells and a sevenfold increase in CD8+ T-cells were achieved with the OX40 mRNA-conjugated T-cell aptamer.
- The novel drug delivery platform targets immune cells to improve mRNA therapeutics.
- Efficient delivery of mRNA to T-cells is facilitated by aptamer-mRNA conjugation.
- The platform demonstrates potential for customization to target other specific cells.
- Enhanced mRNA transfection was observed in murine ex vivo splenocyte T-cells.
Simplified